Menu

Rothwell Figg BiosimilarIP Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

News

Random entry RSS

You are here:

  1. Home
  2. Tag Archives: News
  • Posted in:

    • News

    Celltrion’s Application for Rituxan® (rituximab) Biosimilar Accepted by FDA

    By C. Nichole Gifford July 3, 2017 Comments are off

    Celltrion announced last week that its Biologics License Application (“BLA”) for CT-P10, a biosimilar to Biogen and Genentech’s...

    Read more

    Tagged with: Biogen, Celltrion, FDA, Genentech, News, Regulatory, Rituxan®, Rituximab, Teva

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Sandoz’s Rixathon® (rituximab) Approved in Europe

    By Andrew Storaska June 29, 2017 Comments are off

    On June 19, 2017, the European Commission (EC) approved Sandoz’s Rixathon® (rituximab), a biosimilar to Roche/Genentech’s...

    Read more

    Tagged with: EMA, FDA, Genentech, Mabthera, News, Regulatory, Rituxan®, Rituximab, Rixathon®, Sandoz

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    FDA Unexpectedly Rejects Pfizer’s Application for an Epoetin Alfa Biosimilar (Again)

    By C. Nichole Gifford June 28, 2017 Comments are off

    We previously reported that after a public meeting held on May 25, 2017, the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended...

    Read more

    Tagged with: Amgen, epoetin alfa, Epogen®, FDA, Hospira, News, Pfizer, Regulatory

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Samsung Bioepis’ Imraldi® (adalimumab) Recommended for Approval in Europe

    By C. Nichole Gifford June 26, 2017 Comments are off

    On June 22, 2017, the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicine’s Agency (“EMA”)...

    Read more

    Tagged with: AbbVie, adalimumab, Biogen, EMA, FDA, Humira®, Imraldi®, News, Regulatory, Samsung Bioepsis

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Fujifilm Kyowa Kirin Biologics Announces Application for Humira® (Adalimumab) Biosimilar Accepted by EMA

    By C. Nichole Gifford June 8, 2017 Comments are off

    Fujifilm Kyowa Kirin Biologics announced that its Medical Marketing Application (“MMA”) for FKB327, a biosimilar to AbbVie’s Humira®...

    Read more

    Tagged with: AbbVie, adalimumab, AstraZeneca, Avastin®, bevacizumab, EMA, FDA, Fujifilm Kyowa Kirin, Humira®, News, Regulatory

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    FDA Advisory Committee Meeting Announced for Amgen’s and Allergan’s Proposed Biosimilar to Avastin® (Bevacizumab)

    By C. Nichole Gifford June 8, 2017 Comments are off

    The FDA announced yesterday that the Oncologic Drug Advisory Committee (“ODAC”) has scheduled a public meeting to review ABP 215,...

    Read more

    Tagged with: Allergan, Amgen, Avastin®, bevacizumab, FDA, Genentech, News, Regulatory

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Pfizer Challenges Genentech’s Carter ’213 Antibody Patent With Two New IPR Petitions

    By C. Nichole Gifford June 2, 2017 Comments are off

    On May 25, 2017, Pfizer, Inc. (“Pfizer”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, Hospira, IPR, Legal, Mylan, News, Pfizer, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Amgen’s Epogen®/Procrit® (epoetin alfa)

    By C. Nichole Gifford May 31, 2017 Comments are off

    Pfizer announced last week that the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended its proposed biosimilar to Amgen’s...

    Read more

    Tagged with: Amgen, Amgen v. Hospira, BPCIA, epoetin alfa, Epogen®, FDA, Hospira, Janssen, News, Pfizer, Procrit®, Regulatory, Retacrit®

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion Challenges Another Herceptin® Patent With Two New IPR Petitions

    By C. Nichole Gifford May 18, 2017 Comments are off

    Last week, Celltrion, Inc. (“Celltrion”) filed two new petitions for inter partes review (“IPR”) of U.S. Patent No. 6,407,213...

    Read more

    Tagged with: Celltrion, Genentech, Herceptin®, IPR, Legal, News, PTAB, Roche, Teva, trastuzumab, USPTO

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

Pages

  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • Next

Sign Up for Updates

Don’t worry. We don’t spam.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

  • Seth Cockrum

Featured Posts

  • U.S. – E.U. Mutual Recognition Agreement Will Reduce Costs

    August 1, 2019

  • House Democrats Seek to Remove Biologics Exclusivity Period From USMCA

    July 25, 2019

  • What Pharma Companies Must Do Globally to Benefit From Canada’s Patent Term Extension Framework

    July 22, 2019

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen Boehringer Ingelheim BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Publications
  • News & Events
  • Professionals

© 2019 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top